Corcept Therapeutics CORT Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's financing cash flow?
- Corcept Therapeutics (CORT) reported financing cash flow of $760K in Q1 2026.
- How has Corcept Therapeutics's financing cash flow changed year-over-year?
- Corcept Therapeutics's financing cash flow increased by 101.9% year-over-year, from -$39.8M to $760K.
- What is the long-term trend for Corcept Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Corcept Therapeutics's financing cash flow has grown at a -7.6% compound annual growth rate (CAGR), from -$302.59M to -$220.37M.
- What does financing cash flow mean?
- The net change in cash resulting from transactions with shareholders and creditors.
- How do you interpret financing cash flow?
- Negative values often indicate debt repayment or significant share repurchases, while positive values suggest capital raising activities.
- How does financing cash flow compare across companies?
- A standard line item in the cash flow statement across all public companies; essential for assessing capital structure changes.